NCT01852591

Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant

Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

There is no study hypothesis. The purpose of this study is to see if the Pneumococcal conjugate vaccine (PCV13), when administered before and early after an autologous peripheral stem cell transplant will induce an immune response.

Detailed description

This is a pilot study to determine the safety of PCV13 administered to patients with myeloma before and at +7-10 days and +21-24 days after autologous hematopoietic stem cell transplant; and,to quantify the immune response induced by PCV13 vaccination in patients with myeloma when administered before and early after autologous PSCT.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	PCV 13

Timeline

• Start date: 2013-02-01
• Primary completion: 2015-02-01
• Completion: 2016-10-01
• First posted: 2013-05-13
• Last updated: 2017-02-02
• Results posted: 2016-04-04

Locations

1 site across 1 country: United States